PPP1R12A / Protein phosphatase 1 regulatory subunit 12A · IHC design guide

Design Immunohistochemistry for PPP1R12A

Plan chromogenic PPP1R12A IHC in paraffin sections using the IHC-validated antibody (datasheet PB9737). Compare staining with the cytoplasmic and membranous tissue pattern (HPA tissue IHC), and check epitope coverage across the 5 reported isoforms (UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for PPP1R12A (IHC for PPP1R12A): expected localisation Cytoplasmic and membranous staining in most cells (HPA tissue IHC), antibody PB9737, validated IHC image, and IHC protocol steps — Printable **PPP1R12A** IHC protocol sheet — expected localisation Cytoplasmic and membranous staining in most cells (HPA tissue IHC), antibody PB9737, controls and protocol steps. Open the full PPP1R12A IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

PPP1R12A Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic and membranous staining in most cells (HPA tissue IHC)
	Staining pattern	Most cells show cytoplasmic and membranous staining (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB9737)
	Positive control ⓘ	Appendix+4 more · see all
	Negative control ⓘ	Adipose tissue

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Adipocytes may lack staining despite broad positivity (HPA tissue IHC)
	Regulation	Staining intensity regulation is unreported (UniProt)
	Isoform / epitope	5 isoforms; confirm epitope coverage across variants (UniProt)

Section 1

Recommended PPP1R12A IHC & IF Protocols

Compare the catalog antibody’s citrate pH 6 IHC-P protocol (datasheet PB9737) with published chromogenic IHC methods for cholangiocarcinoma tumor tissue (PMC8210562) and pancreatic tissue (PMC4843125).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded Human Glioma tissue; fixative not specified (datasheet PB9737)
Fixation	Image fixative and duration unreported (datasheet PB9737); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB9737)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9737)
Primary antibody	Rabbit anti-PPP1R12A, 0.5-1μg/ml (datasheet PB9737)
Primary incubation	Overnight at 4 °C (datasheet PB9737)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9737)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	PPP1R12A-positive staining in lymphoid tissue of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in most cells. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet PB9737); the cholangiocarcinoma protocol used citrate pH 6.0 at 96°C for 30 minutes (PMC8210562).

Section 2

What Is the Expected PPP1R12A Staining Pattern?

PPP1R12A is a cytoplasmic, stress fiber associated protein without a transmembrane segment (UniProt O14974 topology and subcellular location). In paraffin section IHC, expect cytoplasmic and membranous staining in many cell types, with high staining reported in selected epithelial, neuronal, and lymphoid cells (HPA tissue IHC). The tissue profile is Approved, with medium consistency between antibody staining and RNA expression; treat individual staining results as observations rather than absolute expression rules (HPA tissue IHC).

What am I looking at on my slide?
Cytoplasmic staining, sometimes outlining cells, in glandular epithelium or other expected cells.	This fits HPA’s cytoplasmic and membranous IHC profile. High staining is reported in breast and endometrial glandular cells, among others (HPA tissue IHC). Judge intensity against a control section stained in the same run (general IHC practice).
Predominantly nuclear staining with little cytoplasmic signal.	A nuclear dominant IHC pattern is discordant with the reported tissue profile (HPA tissue IHC). Nucleolar localization is uncertain in ICC-IF, so it does not establish a nuclear IHC pattern (HPA subcellular). Check staining controls before interpreting this as PPP1R12A.
Strong adipocyte staining while expected positive cells also stain.	Adipocytes are listed as not detected, whereas several glandular and neuronal cell groups are high (HPA tissue IHC). Consider nonspecific antibody binding or endogenous chromogen activity; check a no primary control and compare cell types on the same section (general IHC practice).
Broad, even chromogen deposit across cells and extracellular areas.	This distribution is hard to assign to the reported cytoplasmic and membranous pattern (HPA tissue IHC). Review the no primary control, blocking, washes, and detection steps for background (general IHC practice); background alone cannot identify its cause.
No staining in a breast glandular or bronchial epithelial control.	Both cell groups have high reported staining, so an absent signal calls for a run level check (HPA tissue IHC). Confirm that the expected cells are present and assess antibody, retrieval, detection, and counterstain using the assay instructions (general IHC practice).

💡Expected PPP1R12A appearanceCall a result positive when identifiable cells show cytoplasmic, sometimes membranous staining, with strong examples in HPA high cell groups; an exclusively nuclear pattern or uniform deposit outside cells is suspect (HPA tissue IHC; general IHC practice).

How each factor affects the staining
Compartment and morphology	UniProt places PPP1R12A in cytoplasm and along actomyosin filaments; HPA tissue IHC reports cytoplasmic and membranous expression (UniProt O14974 subcellular location; HPA tissue IHC). Fine filament detail may be difficult to resolve in chromogenic sections (general IHC practice).
Cell type and tissue	HPA reports high staining in appendix lymphoid tissue, bronchial respiratory epithelium, cerebral cortical neurons, and several glandular cell groups; adipocytes are not detected (HPA tissue IHC). A negative adipocyte area is a useful comparison, but it cannot replace a positive control (general IHC practice).
Strength of IHC evidence	The tissue profile is Approved and has medium antibody staining versus RNA consistency (HPA tissue IHC). HPA071956 is IHC Approved; no IHC status is supplied for HPA041296 (HPA antibodies). These labels support pattern comparison without guaranteeing every specimen or antibody result.
Isoforms and antibody recognition	UniProt lists five PPP1R12A isoforms (UniProt O14974 isoforms). The payload gives no epitope or isoform recognition data for an IHC antibody, so differences among isoforms cannot be assigned from staining alone.
IF/ICC Q&A: what localization is supported?	Mainly cytosol and actin filaments; nucleoli and plasma membrane are additional uncertain locations (HPA subcellular ICC-IF). Use those observations to interpret IF/ICC images, while keeping chromogenic tissue interpretation anchored to the HPA tissue IHC profile.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Expected positive cells are blank.	The run may have failed, or the sampled section may lack the relevant cells; HPA lists high staining for breast glandular and bronchial respiratory epithelial cells (HPA tissue IHC).	Verify cell identity and a same run positive control. Review antibody use, retrieval, detection, and counterstain against the assay instructions (general IHC practice).
Adipocytes stain strongly.	This conflicts with HPA’s not detected adipocyte observation; nonspecific binding or endogenous chromogen activity is possible (HPA tissue IHC; general IHC practice).	Compare an adjacent no primary control, inspect deposit distribution, and review blocking and detection controls (general IHC practice).
Signal is mainly nuclear.	It differs from the cytoplasmic and membranous tissue profile; ICC-IF nucleolar localization is uncertain (HPA tissue IHC; HPA subcellular).	Recheck the scored cell type and controls. Avoid scoring isolated nuclear signal as a confirmed positive without supporting cytoplasmic staining (general IHC practice).
Background obscures cell borders.	Excess chromogen or nonspecific detection can obscure the reported cytoplasmic and membranous distribution (general IHC practice; HPA tissue IHC).	Inspect the no primary control and review blocking, wash, detection, and chromogen steps before scoring compartments (general IHC practice).
Staining varies between tissue regions.	Cell composition may differ across regions; HPA reports high, low, and not detected staining across specified cell groups (HPA tissue IHC).	Score comparable cell types separately and record intensity and the proportion of stained cells. Compare with controls processed in the same run (general IHC practice).
Two antibodies give different patterns.	HPA071956 has IHC Approved status, while no IHC status is supplied for HPA041296; this record cannot establish the cause of disagreement (HPA antibodies).	Compare each result with HPA’s tissue compartments and cell types, then check each antibody’s controls and assay instructions before assigning specificity (HPA tissue IHC; general IHC practice).

Source: UniProt O14974 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing PPP1R12A staining

IHC analysis of PPP1R12A using anti-PPP1R12A antibody (PB9737). PPP1R12A was detected in paraffin-embedded section of Human Glioma Tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-PPP1R12A Antibody (PB9737) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9737 · IHCIHC analysis of PPP1R12A using anti-PPP1R12A antibody (PB9737). PPP1R12A was detected in paraffin-embedded section of Human Glioma Tissue. H

M01743-1 · IHCHuman placenta was stained with anti-MYPT1 rabbit antibody

IF analysis of PPP1R12A using anti-PPP1R12A antibody (PA1681). PPP1R12A was detected in immunocytochemical section of SiHa cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 2μg/mL rabbit anti-PPP1R12A Antibody (PA1681) overnight at 4°C. DyLight®488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:100 dilution and incubated for 30 minutes at 37°C. The section was counterstained with DAPI. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

PA1681 · IFIF analysis of PPP1R12A using anti-PPP1R12A antibody (PA1681). PPP1R12A was detected in immunocytochemical section of SiHa cells. Enzyme ant

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000058272-PPP1R12A/tissue/cerebral+cortex#imid_20166373

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000058272-PPP1R12A/tissue/colon#imid_20165435

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000058272-PPP1R12A/tissue/liver#imid_20165452

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000058272-PPP1R12A/tissue/kidney#imid_20165437

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA041296; green = PPP1R12A, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for PPP1R12A IHC & IF

🧪Run breast first: glandular cells should stain (HPA: High in breast glandular cells). Run adipose tissue as the negative comparator (HPA: Not detected in adipocytes); adipocytes present on the breast slide, if any, should show background-level staining, while other cell types should not be presumed negative without evidence (HPA: Not detected in adipocytes).

Positive control tissue: Appendix (Lymphoid tissue, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PPP1R12A in A-431, U-251MG, U2OS, RT-4, SiHa, RPTEC/TERT1, hTERT-RPE1 (serum starved), NIH 3T3, with annotated localisation: Actin filaments (supported), Cytosol (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG isotype control matched to the primary antibody’s clonality where applicable (caption: rabbit primary; standard IHC practice). Use PPP1R12A knockout material as a biological specificity control, quench endogenous peroxidase, and check for endogenous biotin because the reported detection uses a biotinylated secondary, streptavidin–biotin complex and DAB (caption: detection method; standard IHC practice).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected PB9737 paraffin-section caption does not state a fixative (caption: fixative unreported). The caption reports citrate retrieval at pH 6 for 20 minutes, but does not establish that retrieval is required; the supplied evidence does not establish whether frozen sections or IF are easier (caption: retrieval conditions; HPA: ICC-IF images). In breast sections, score glandular cytoplasm against adjacent adipocytes cautiously because paraffin processing leaves adipocytes with little visible cytoplasm (HPA: High in breast glandular cells; HPA: Not detected in adipocytes; standard histology practice).

HPA tissue IHC evidence for PPP1R12A

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Appendix	Lymphoid tissue	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Cerebral cortex	Neuronal cells	High	Protein (IHC)	HPA →
Endometrium	Glandular cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced PPP1R12A IHC Tips

Troubleshooting chromogenic IHC for PPP1R12A in paraffin sections, with one companion IF/ICC question.

How should I retrieve PPP1R12A in paraffin sections when staining is weak?

Use heat-mediated citrate retrieval at pH 6 for 20 minutes before chromogenic IHC (datasheet PB9737; caption PB9737). The documented paraffin-section image used this treatment, followed by 10% goat serum and 1 μg/mL primary antibody overnight at 4°C (caption PB9737). If staining remains weak, compare retrieval duration across adjacent sections while keeping antibody concentration, detection, and development consistent (standard IHC practice). Include a tissue region expected to stain, such as breast glandular cells, to distinguish retrieval failure from low local expression (HPA: High in breast glandular cells). Inspect section integrity alongside signal, because aggressive heating can damage morphology and complicate scoring (standard IHC practice).

Does fixation explain variable PPP1R12A staining between paraffin blocks?

Target-specific fixation sensitivity is unknown because the selected paraffin-section caption does not state a fixative (caption PB9737). Do not treat its successful staining in human glioma tissue as evidence for a particular fixation method or duration (caption PB9737). Compare blocks with documented processing histories and run them together using citrate retrieval at pH 6 for 20 minutes (datasheet PB9737; standard IHC practice). Keep section thickness, antibody incubation, and chromogen development consistent while evaluating morphology and staining intensity (standard IHC practice). If processing histories differ, report that limitation when attributing a staining difference to biological expression (standard IHC practice).

Where should I expect PPP1R12A staining, and how should I assess membrane-like signal?

Expect predominantly cytoplasmic staining compatible with the cytosol and actomyosin-associated structures (UniProt O14974 subcellular location; HPA subcellular: supported cytosol and actin filaments). Tissue IHC also describes cytoplasmic and membranous expression in most cells, so a membrane-like outline alone is not grounds for rejection (HPA tissue IHC profile). PPP1R12A has no annotated transmembrane segment, and plasma-membrane localisation is uncertain in the subcellular dataset (UniProt O14974 topology; HPA subcellular: uncertain plasma membrane). Compare the outline with cytoplasmic signal, tissue architecture, and controls on the same run (standard IHC practice). Treat isolated nuclear or nucleolar staining cautiously because nucleolar localisation is reported with uncertain support (HPA subcellular: uncertain nucleoli).

Can this stain distinguish PPP1R12A isoforms or phosphorylation states?

The record lists 5 PPP1R12A isoforms, but the supplied antibody caption does not map its epitope to any isoform (UniProt O14974 isoforms; caption PB9737). Therefore, a positive chromogenic stain cannot by itself identify which isoform produced the signal (UniProt O14974 isoforms; standard IHC interpretation). The protein also has annotated modified residues, including phosphoserines at positions 299 and 422 (UniProt O14974 modified residues). Do not interpret intensity as a phosphorylation readout without evidence that this antibody distinguishes a defined modified epitope (standard IHC practice). For an isoform or modification claim, establish epitope coverage and validate specificity with appropriate independent controls (standard IHC practice).

How can IF help resolve PPP1R12A staining without overinterpreting the IHC result?

For a separate IF/ICC assessment, compare PPP1R12A with a validated marker of the expected cell type, such as a glandular-cell marker in breast sections (HPA: High in breast glandular cells; standard IF practice). Choose fluorophores and imaging channels after checking tissue autofluorescence; a spectrally separated far-red channel can improve contrast when shorter wavelengths are bright (standard IF practice). PPP1R12A is cytosolic and actin-associated, with no annotated transmembrane segment, so access to an intracellular epitope may require permeabilisation (UniProt O14974 subcellular location and topology; standard IF practice). Because the antibody epitope is unspecified, optimise permeabilisation against cell morphology and signal retention rather than assuming a known membrane-facing side (caption PB9737; standard IF practice). Use single-channel and secondary-only controls to assess bleed-through and nonspecific fluorescence (standard IF practice).

What should I check when PPP1R12A IHC shows diffuse brown background?

The selected image used 10% goat serum, biotinylated secondary antibody, a streptavidin–biotin detection complex, and DAB (caption PB9737). Check a no-primary section and a secondary-only section to locate background introduced by detection reagents (standard IHC practice). With this detection chemistry, assess endogenous biotin and apply an appropriate block if it contributes signal (caption PB9737; standard IHC practice). Quench endogenous peroxidase for a peroxidase–DAB workflow, and compare signal after adequate washing and controlled chromogen development (standard IHC practice). If background persists, titrate the primary around the documented 1 μg/mL condition while preserving a positive reference section in each run (caption PB9737; standard IHC practice).

How should I quantify PPP1R12A across tissue regions? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and region before scoring, then record cytoplasmic intensity and the percentage of positive cells for an H-score (standard IHC practice; UniProt O14974 subcellular location). Alternatively, report positive-cell density per mm² when cell counts and sampled area are reliably defined (standard IHC practice). Normalise the denominator to viable cells of the chosen population or to the measured viable tissue area, and exclude necrotic or folded regions (standard IHC practice). Keep retrieval, 1 μg/mL primary incubation, detection, imaging, and positivity thresholds consistent across compared sections (caption PB9737; standard IHC practice). Record compartment-specific scores separately when cytoplasmic and membrane-like patterns differ (HPA tissue IHC profile; standard IHC practice).

How can I distinguish genuine PPP1R12A staining from IHC artefact?

A credible result should show interpretable cytoplasmic staining in intact cells, consistent with PPP1R12A localisation and the tissue IHC profile (UniProt O14974 subcellular location; HPA tissue IHC profile). Use an expected positive population, such as breast glandular cells, and a comparison population such as adipocytes, where staining was not detected (HPA: High in breast glandular cells; HPA: Not detected in adipocytes). Question signal confined to section edges, folds, or necrotic regions, especially when adjacent intact cells lack the pattern (standard IHC practice). Check no-primary controls for endogenous enzyme activity and detection-related colour before assigning weak DAB signal to PPP1R12A (standard IHC practice). Interpret isolated nucleolar staining cautiously because that location has uncertain support (HPA subcellular: uncertain nucleoli).

Boster reagents

Best PPP1R12A / Protein phosphatase 1 regulatory subunit 12A IHC Antibodies

The catalog shows human glioma paraffin-section IHC, human placenta staining, and SiHa-cell IF/ICC images (PB9737, M01743-1, and PA1681 image captions). Listed reactivity spans human, monkey, mouse, and rat (catalog reactivity).

Real IHC data

Anti-Myosin Phosphatase/PPP1R12A Antibody ®

Cat # PB9737

View product →

Real IHC data Human placenta was stained with anti-MYPT1 rabbit antibody

Anti-MYPT1 Rabbit Monoclonal Antibody

Cat # M01743-1

View product →

Real IF data

Anti-Myosin Phosphatase/PPP1R12A Antibody ®

Cat # PA1681

View product →

PB9737 shows human glioma paraffin-section IHC, while M01743-1 shows human placenta staining and lists IHC as an application (respective image captions; M01743-1 catalog applications). PA1681 shows IF/ICC in SiHa cells and lists human, monkey, mouse, and rat reactivity (PA1681 image caption; catalog reactivity).

Which to pick: For chromogenic tissue IHC, choose PB9737 for its documented human paraffin-section staining with citrate retrieval and DAB detection; its fixative is unreported (PB9737 image caption). M01743-1 offers a human-reactive rabbit monoclonal with a placenta IHC image, though its caption does not report processing conditions (M01743-1 catalog description, reactivity, applications, and image caption). For IF/ICC, choose PA1681 for its SiHa-cell image; for work across species, PB9737 lists human, monkey, mouse, and rat reactivity, but its pictured tissue IHC is human only (PA1681 image caption and applications; PB9737 catalog reactivity and image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry O14974 (MYPT1_HUMAN, Protein phosphatase 1 regulatory subunit 12A).
Human Protein Atlas. PPP1R12A tissue IHC expression (reliability: Approved).
Human Protein Atlas. PPP1R12A subcellular location (ICC-IF): Mainly localized to the cytosol and actin filaments. In addition localized to the nucleoli and plasma membrane..
Human Protein Atlas. PPP1R12A antibody validation summary (2 antibodies).
MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects. Journal of Cancer 2021 — PMC8210562.
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer. Frontiers in genetics 2021 — PMC8414655.
Trans-Synaptic Signaling through the Glutamate Receptor Delta-1 Mediates Inhibitory Synapse Formation in Cortical Pyramidal Neurons. Neuron 2019 — PMC6926483.
Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer immunology research 2016 — PMC4843125.
PubMed PMID:9286714 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:16541075 — UniProt-cited evidence.